Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Disease Progression × durvalumab × 90 days × Clear all

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 38 Lung Neoplasms 25 Small Cell Lung Carcinoma 18 Carcinoma, Hepatocellular 18 Urinary Bladder Neoplasms 10 Liver Neoplasms 9 Biliary Tract Neoplasms 9 Neoplasms 6 Stomach Neoplasms 5 Cholangiocarcinoma 5 Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Ovarian Neoplasms 4 Carcinoma 4 Triple Negative Breast Neoplasms 3 Respiratory Tract Neoplasms 3 Neoplasms by Site 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Transitional Cell 3 Adenocarcinoma 3 Uterine Cervical Neoplasms 2 Thoracic Neoplasms 2 Respiratory Tract Diseases 2 Pathologic Complete Response 2 Pancreatic Neoplasms 2 Oropharyngeal Neoplasms 2 Neoplasm Metastasis 2 Mouth Neoplasms 2 Mesothelioma, Malignant 2

Interventions

capivasertib 2 niraparib 1 lutetium Lu 177 dotatate 1 fludarabine phosphate 1 fludarabine 1 copanlisib 1 axicabtagene ciloleucel 1 Receptors, Interleukin-6 1 Interleukin 1 Receptor Antagonist Protein 1 Fulvestrant 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡